Q3 Season Close: CXO Recovery Is Not Broad-Based — It's a Gradient Down the R&D Chain

With Q3 filings now in, China's CXO sector has delivered an uneven scorecard: WuXi AppTec's chemistry revenue grew 51.52%, Medicilon turned profitable and JOINN Laboratories posted a profit jump of more than 10x, while Asymchem's non-IFRS net profit grew just 0.04% and Jiuzhou Pharma declined on both lines. The unifying explanation: demand recovers in a gradient from preclinical to downstream, fuelled by the US biotech IPO reopening, BD upfront payments flowing back, and AI-native wet-lab orders. The recovery is real — but each segment's pay-off point differs.

With 2026 Q3 filings closed, the CXO sector's direction and rhythm can finally be read on one page. CLS (Cailianshe)'s 1 November survey identifies three drivers rarely seen together before: improved US biotech funding and a reopened IPO window, upfront payments flowing back from China's license-out deals, and AI drug-discovery companies bringing genuine wet-lab orders. But demand does not arrive at every link simultaneously — it travels down the R&D chain from discovery to manufacturing, and companies' order recovery and earnings realisation have diverged accordingly.

Cold and hot on the same chain

Preclinical felt the warmth first. Medicilon's nine-month revenue rose 44.13% to RMB 1.215 billion, swinging to a net profit of RMB 92 million, with gross margin up 10.38 points to 30.72%; the company's IR contact noted that beyond demand recovery, safety-evaluation capacity had been tight for about a year 'with clearly rising prices', reversing the discounting of the downturn. JOINN Laboratories posted nine-month net profit of RMB 930 million, up 1,051.94%, with RMB 866 million from fair-value gains on research monkeys — the monkey cycle's reversal is itself a mirror of preclinical demand. Downstream CDMO shows 'revenue first, profit later': Asymchem grew nine-month revenue 16.52% to RMB 5.395 billion but non-GAAP net profit just 0.04%, with operating cash flow down 47.10%; delivery of late-stage and commercial orders is concentrated in H2 with a significantly larger Q4. Jiuzhou Pharma declined on both lines. At the top, WuXi AppTec's chemistry revenue rose 51.52% to RMB 39.362 billion — D&M up 65.6% to RMB 23.58 billion — with backlog of RMB 76.74 billion, up 36.4%.

Where demand comes from: IPO reopening and upfronts

Two data sets explain the quality of this recovery. Overseas: 22 US biotech IPOs raised about USD 6.9 billion in the first three quarters of 2026, versus 7 deals and USD 1.4 billion in all of 2025 — the funding ammunition for early-stage outsourcing is refilling fast. Domestic: China's H1 license-out volume reached 100 deals worth USD 99.7 billion, with upfronts flowing back and MNC partnerships extending. Client structures confirm it: Pharmaron's nine-month revenue from North American clients grew 10.10%, Europe 30.07% and mainland China 39.09%; Asymchem's domestic revenue grew 42.83% with overseas up 11.64% at constant currency. The industry consensus, as analyst Liu Yuqi put it, is a 'structurally recovering' phase — overseas demand stronger than domestic, new modalities stronger than legacy — with GLP-1 peptides, ADCs and oligonucleotides capacity-tight while conventional antibodies and standard small molecules still compete on price.

The sector lens: three curves all turning positive

Sinolink Securities' 1 November Q3 review provides sector-level validation: CDMO revenue growth accelerated from 17% in 2025 to 28% in Q3 filings, up from 26% at the interim; CRO turned positive at 16% growth (from -8% in 2024 and -3% in 2025, 13% at the interim); and life-science research upstream accelerated to 25% revenue growth with non-GAAP net profit up 55% as operating leverage released. The report attributes the driver to concentrated demand from new modalities — GLP-1, ADC, peptides, oligonucleotides — plus recovering domestic funding, describing an upcycle of 'domestic-overseas resonance with orders converting quarter by quarter'.

Editor's note: decompose 'recovery' into a three-stage test

The gradient framework's value for practitioners is the time lag it exposes: preclinical heats first (Medicilon and JOINN Laboratories have validated new signings and pricing), clinical CRO sits in between (Tigermed's non-GAAP profit up 38.08%), and CDMO profit realisation comes last (Asymchem's flat non-GAAP profit and pressured cash flow, Q4 concentrated delivery). Rather than watching for a broad rally, track a three-link evidence chain: orders (new signings and backlog), revenue (delivery rhythm), profit (margin and cash-flow repair). From Q4 into next H1, the watch point shifts from 'did orders arrive' to 'did profit follow' — that is the signal that this structural recovery is becoming a full one.